Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.

Kerschbaumer, Andreas; Smolen, Josef S; Dougados, Maxime; de Wit, Maarten; Primdahl, Jette; McInnes, Iain; van der Heijde, Désirée; Baraliakos, Xenofon; Falzon, Louise; Gossec, Laure

Kerschbaumer, Andreas; Smolen, Josef S; Dougados, Maxime; de Wit, Maarten; Primdahl, Jette; McInnes, Iain; van der Heijde, Désirée; Baraliakos, Xenofon; Falzon, Louise; Gossec, Laure.

Afiliação

Kerschbaumer A; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria andreas.kerschbaumer@meduniwien.ac.at.
Smolen JS; Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
Dougados M; Hopital Cochin, Rheumatology, Université Paris Descartes, Paris, France.
de Wit M; EULAR past Vice President representing People with Arthritis/Rheumatism in Europe (PARE), Zurich, Switzerland.
Primdahl J; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark.
McInnes I; Department of Regional Health Research, University of Southern Denmark, Odense, Syddanmark, Denmark.
van der Heijde D; Hospital of Southern Jutland, University Hospital of Southern Denmark, Aabenraa, Denmark.
Baraliakos X; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
Falzon L; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Gossec L; Rheumazentrum Ruhrgebiet, Ruhr-Universität Bochum, Herne, Germany.

Ann Rheum Dis ; 79(6): 778-786, 2020 06.

Article em En | MEDLINE | ID: mdl-32381564

Assuntos

Antirreumáticos/uso terapêutico; Artrite Psoriásica/tratamento farmacológico; Produtos Biológicos/uso terapêutico; Antirreumáticos/efeitos adversos; Produtos Biológicos/efeitos adversos; Humanos; Interleucina-17/antagonistas & inibidores; Subunidade p19 da Interleucina-23/antagonistas & inibidores; Terapia de Alvo Molecular; Medicamentos Sintéticos/uso terapêutico; Fator de Necrose Tumoral alfa/antagonistas & inibidores

Palavras-chave

DMARDs (biologic); DMARDs (synthetic); anti-TNF; psoriatic arthritis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Artrite Psoriásica / Antirreumáticos Tipo de estudo: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google